Published on November 16, 2007
Comparative Oncology: Companion Animal Cancer Models Large outbred Animals Strong Genetic similarities to Humans Naturally Occurring cancers Immune competant and syngeneic Relevant Tumor Histology/Genetics Relevant Response Profiles to Conventional Chemotherapy Tumor Heterogeneity Metastasis Biology Recurrence/Resistance Cancer IN Companion Animals 65 Million Companion Animals in the US 4 million pet dogs diagnosed with cancer each year Pet owners seek advanced care for their pets Comparative Oncology TO PROVIDE OPPORTUNITIES TO INCLUDE NATURALLY OCCURRING CANCER MODELS IN THE STUDY OF CANCER BIOLOGY AND THERAPY Slide4: The CCR - Comparative Oncology Program Develop essential reagent kit for the study of comparative models in translational and biology-based research; Develop multicenter collaborative network with extramural comparative oncology programs. Within this network design, implement and manage pre-clinical trials involving pet animals that will evaluate novel therapeutic strategies for cancer; Increase the awareness of the appropriate use of naturally occurring cancer models within the cancer research community; Slide5: Resources and Reagents: opportunities for Layered Translation Slide6: Comparative Oncology Trials Consortium (COTC) Integration of a Comparative Approach: Integration of a Comparative Approach Activity Toxicity Pharmacokinetics Pharmacodynamics Dose Regimen Schedule Biomarkers Responding Histologies Combination therapies Phase III Human Clinical Trials Phase II Human Clinical Trials New Cancer Drug Slide9: Large Pharma Merck Status: CDA in place, meeting to discuss collaborations has been scheduled for early January 2006. Astrazeneca Status: Meeting is planned for mid-November to discuss a trial in pet dogs. Small Pharma/Biotech Genzyme Status: CRADA meeting and presentation completed. Locus Pharmaceuticals Status: CDA has been completed and a Trial Overview is being drafted. Slide10: Academia/Biotech SemaCo Status: CDA IN PLACE, in vitro evaluation underway (T Olgios in canine OSA cell lines) Colando Pharmaceuticals Status: Currently validating their anti-RRM2 antibody in canine normal and tumor tissues by Western and Immunohistochemical analysis. Center for Cancer Research Radiation Oncology (Jim Mitchel) Tempol Evaluation of intravenous Tempol in pet dogs receiving fractionated radiation therapy in dogs with head and neck cancer Status - Trial overview in second review Surgery Branch (Steve Libutti) Phage Delivery of TNF- Evaluation of RGD Targeted Delivery of Phage Expressing TNF- To Tumor Bearing Dogs Status - Trial approved for initiation Slide11: News Nature Medicine 11, 1018 (2005) Published online: 28 September 2005; | doi:10.1038/nm1005-1018a Cancer researchers usher in dog days of medicine George S Mack Columbia, South Carolina After thousands of years of friendship, man and dog will soon be working together to advance drug discovery. As part of a new comparative-oncology program at the US National Cancer Institute, researchers are set to begin drug trials in dogs that aim to bridge the gap between preclinical drug studies and effects of the same drug in people. Two multicenter trials, set to begin in early 2006, will evaluate new therapeutic approaches for cancer in dogs, says program chief Chand Khanna, a veterinary oncologist at the institute's Center for Cancer Research. "It turns out that many cancers, such as lymphoma, melanoma and osteosarcoma, are well represented in pet dogs," Khanna says. "The dogs will help us prioritize the agents that go into human clinical trials and help make those trials more efficient." Wall Street Journal July 7, 2005 Nature Medicine October 2005 The Good News…We have arrived. Now we must deliver Acknowledgments: Acknowledgments Comparative Oncology Program CCR, National Cancer Institute Melissa Paoloni Christina Mazcko Katherine Hansen Tumor and Metastasis Biology Section, PEDIATRIC ONCOLOGY BRANCH CCR, National Cancer Institute Ling Ren Arnulfo Mendoza Jessica Cassavaugh Rachel Blackwood Sung-Hyeok Hong Lauren Shapiro Ben Bruce Rachel Newman Gaurav Khanna Acknowledgments: Acknowledgments Molecular Oncology Section Pediatric Oncology Branch CCR, National Cancer Institute Xiaolin Wan Choh Yeung Lee Helman Tissue Array Research Project (TARP), CCR Stephen Hewitt Kimberly Parker Biomedical Proteomics Program, CCR LiRoung Yu Ming Zhou Tim Veenstra Cornell University Anthony Bretscher Columbia University Charles Powell Alain Borczuk University of Michigan Evan Keller University of Umea Goran Landberg State University of Ohio Mark Berryman LCMB, CCR, National Cancer Institute Yanlin Yu Glenn Merlino Cancer Genetics Branch, NHGRI Kristin Baird Paul Meltzer Oncogenomics Section, POB, NCI Javed Khan Carcinogenesis/Prevention, CCR Nancy Colburn
http://ctos.org/meeting/2005/presentations/Saturday/am0845_Khanna.ppt Download Preclinical/Clinical Pipeline - Connective Tissue Oncology ...
Title: Preclinical/Clinical Pipeline Author: NIH NCI Last modified by: Chand Khanna Created Date: 2/28/2004 2:36:30 PM Document presentation format
... Houghton, PhD: cancer modeling Rich Gorlick, MD: osteosarcoma frontiers Antony Tolcher, MD: phase I to sarcomas Chand Khanna, PhD, DVM: ...